RVNC insider transaction filings
Revance Therapeutics, Inc. — 15 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2025-02-06. Screen RVNC transaction legs live →
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2025-02-06 | 4 | Gangolli Julian S — Director | Code (U): 30,106 @ $3.65 · Disposition to issuer (D): 15,000 | EDGAR |
| 2025-02-06 | 4 | Foley Mark J — President & CEO, Director | Code (U): 996,935 @ $3.65 · Code (U): 110,913 @ $3.65 · Disposition to issuer (D): 27,933 · Grant/award (A): 84,686 @ $0 · Disposition to issuer (D): 84,686 | EDGAR |
| 2025-02-06 | 4 | Schilke Tobin — CFO | Code (U): 97,999 @ $3.65 · Disposition to issuer (D): 103,555 · Grant/award (A): 20,883 @ $0 · Disposition to issuer (D): 20,883 | EDGAR |
| 2025-02-06 | 4 | Moxie Dwight — CLO & GC | Code (U): 47,815 @ $3.65 · Disposition to issuer (D): 95,979 · Grant/award (A): 18,125 @ $0 · Disposition to issuer (D): 18,125 | EDGAR |
| 2025-02-06 | 4 | Hollander David — CMO & Global Therapeutics Lead | Code (U): 9,733 @ $3.65 · Disposition to issuer (D): 95,212 | EDGAR |
| 2025-02-06 | 4 | Jordan Erica — Chief Commercial Officer | Code (U): 6,922 @ $3.65 · Disposition to issuer (D): 107,942 | EDGAR |
| 2025-02-06 | 4 | Ware Olivia C — Director | Code (U): 16,675 @ $3.65 · Disposition to issuer (D): 15,000 | EDGAR |
| 2025-02-06 | 4 | Kolaja Carey OConnor — Director | Code (U): 16,561 @ $3.65 · Disposition to issuer (D): 15,000 | EDGAR |
| 2025-02-06 | 4 | Coric Vlad — Director | Code (U): 5,784 @ $3.65 · Disposition to issuer (D): 15,000 | EDGAR |
| 2025-02-06 | 4 | Beraud Jill — Director | Code (U): 28,606 @ $3.65 · Disposition to issuer (D): 15,000 | EDGAR |
| 2025-02-06 | 4 | Nolet Chris — Director | Code (U): 28,606 @ $3.65 · Disposition to issuer (D): 15,000 | EDGAR |
| 2025-02-06 | 4 | Russell Angus C. — Director | Code (U): 36,506 @ $3.65 · Disposition to issuer (D): 15,000 | EDGAR |
| 2025-02-05 | 4 | Foley Mark J — CEO, Director | Grant/award (A): 27,933 @ $0 | EDGAR |
| 2025-02-05 | 4 | Schilke Tobin — CFO | Grant/award (A): 6,888 @ $0 | EDGAR |
| 2025-02-05 | 4 | Moxie Dwight — CLO & GC | Grant/award (A): 5,979 @ $0 | EDGAR |
Recent 8-K events — Revance Therapeutics, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2025-02-06 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.01 — Completion of Acquisition or Disposition of Assets 2.04 — Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 3.03 — Material Modification to Rights of Security Holders 5.01 — Changes in Control of Registrant 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=RVNC returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →